Assessment of target-mediated biodistribution of an 89Zr labeled PD-L1/4-1BB bispecific Mabcalin protein

被引：0
|
作者：
van Winkel, Claudia A.
Fan, Xiaoyu
Giesen, Danique
Gauderat, Glenn
Pattarini, Lucia
Jaquin, Thomas
Barakat, Anissa
De La Bigne, Anne-Marie
Richter, Marleen
Andersen, Nicole
Legrand, Julie
Lelievre, Helene
de Vries, Elisabeth G.
Morales-Kastresana, Aizea
Lub-de Hooge, Marjolijn N.
机构：
来源：
CANCER RESEARCH | 2023年 / 83卷 / 07期
关键词：
D O I：
10.1158/1538-7445.AM2023-3579
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3579
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Radiolabelling and preclinical characterisation of [89Zr]Zr-Df-ATG-101 bispecific to PD-L1/4-1BB
    Cao, Zhipeng
    Wichmann, Christian Werner
    Burvenich, Ingrid Julienne Georgette
    Osellame, Laura Danielle
    Guo, Nancy
    Rigopoulos, Angela
    O'Keefe, Graeme Joseph
    Scott, Fiona Elizabeth
    Lorensuhewa, Nirmal
    Lynch, Kevin Patrick
    Scott, Andrew Mark
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2024, 51 (11) : 3202 - 3214
  • [2] Imaging of PD-L1 modulation by gemcitabine using 89Zr labeled anti-PD-L1 antibody PET.
    Jung, Kyung-Ho
    Park, Jin Won
    Lee, Jin Hee
    Cho, Young Seok
    Lee, Kyung-Han
    CANCER IMMUNOLOGY RESEARCH, 2020, 8 (03) : 90 - 91
  • [3] PD-L1 Crosslinking as a New Strategy of 4-1BB Agonism Immunotherapy
    Shu, Fei
    Punekar, Salman R.
    Velcheti, Vamsidhar
    Sanmamed, Miguel F.
    Wang, Jun
    CLINICAL CANCER RESEARCH, 2022, 28 (15) : 3182 - 3184
  • [4] ATG-101 Is a Tetravalent PD-L1x4-1BB Bispecific Antibody That Stimulates Antitumor Immunity through PD-L1 Blockade and PD-L1-Directed 4-1BB Activation
    Hui, Yuwen
    Wang, Huajing
    Li, Tengteng
    Ren, Yijing
    Zhang, Yun-kai
    Chen, Peng
    Sun, Ao
    Bian, Gang
    Li, Bohua
    Flowers, David
    Presler, Marc
    Subramanian, Kalyanasundaram
    Xue, Jia
    Wang, Jingjing
    Lynch, Kevin
    Mei, Jay
    He, Xiaowen
    Shan, Bo
    Hou, Bing
    CANCER RESEARCH, 2024, 84 (10) : 1680 - 1698
  • [5] Phase 1 trial safety and efficacy of ragistomig, a bispecific antibody targeting PD-L1 and 4-1BB, in advanced solid tumors
    Falchook, Gerald Steven
    LoRusso, Patricia
    Goldman, Jonathan W.
    El-Khoueiry, Anthony B.
    Tolcher, Anthony W.
    Xing, Yan
    Henry, Jason Timothy
    Keam, Bhumsuk
    Kim, Dong-Wan
    Kim, Tae-Yong
    Kim, Hye Ryun
    Hong, Min Hee
    Kim, Min Hwan
    Lee, Dae Ho
    Lee, SangMi
    Jeon, JuYeun
    Hayslip, John W.
    Xu, Cong
    Garon, Edward B.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [6] Is [89Zr]PD-L1 a useful tool to capture an immune response to oncolytic virotherapy?
    Hoebart, J.
    Da Pieve, C.
    Raes, F.
    Ciobota, D. M.
    Smith, G.
    Melcher, A.
    Harrington, K. J.
    Kramer-Marek, G.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2019, 46 (SUPPL 1) : S192 - S193
  • [7] GEN1046 (Bispecific Antibody Targeting PD-L1 and 4-1BB): Preclinical Characteristics and Phase 1 Results in Solid Tumors
    Kunkel, Maria
    Muik, Alexander
    Altintas, Isil
    Gieseke, Friederike
    Schodel, Kristina
    Diken, Mustafa
    Sette, Angelica
    Stanganello, Eliana
    Vascotto, Fulvia
    Breij, Esther
    Sasser, Kate
    Tureci, Ozlem
    Forssmann, Ulf
    Ahmadi, Tahamtan
    Sahin, Ugur
    CANCER SCIENCE, 2023, 114 : 1566 - 1566
  • [8] KEY PHARMACOKINETIC AND PHARMACODYNAMIC PARAMETERS THAT CORRELATE WITH THE ANTI-TUMOR ACTIVITY OF A BISPECIFIC PD-L1 CONDITIONAL 4-1BB AGONIST
    Kinkead, Heather
    Macedo, Chelsie
    Sanabria, Angelica
    Cyprus, Garrett
    Pandit, Rajay
    Kalabus, James
    Becklund, Bryan
    Sulzmaier, Florian
    Timmer, John
    Deveraux, Quinn
    Eckelman, Brendan
    Heidt, Analeah
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 : A12 - A12
  • [9] Immuno PET imaging of PD-L1 expression in syngeneic and human xenograft tumor mouse models using a site-specific 89Zr labeled PD-L1 antibody
    Christensen, Camilla
    Kristensen, Lotte K.
    Toftevall, Hanna
    Nordgren, Maria
    Agnew, Brian J.
    Nielsen, Carsten H.
    Kjaer, Andreas
    CANCER RESEARCH, 2018, 78 (13)
  • [10] The bispecific antibody KA-3004, targeting PD-L1 and 4-1BB, is designed to enhance anti- tumor activity
    Liang, Jiabei
    Guo, Zhengcheng
    Peng, Hao
    Hao, Feng
    Liu, Tongtong
    Ning, Jinying
    Wu, Guojin
    CANCER RESEARCH, 2024, 84 (06)
12345